MedTrace Logo

TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

NCT02796053 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-02-15

No results posted yet for this study

Summary

Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08 during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled with current therapy.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

TAB08

The TAB08 will be administered intravenously, by infusion.

OTHER

Placebo

The Placebo to TAB08 will be administered intravenously, by infusion.

Sponsors & Collaborators

  • Theramab LLC

    lead INDUSTRY

Principal Investigators

  • Daniil Nemenov, M.D. · Theramab LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02796053 on ClinicalTrials.gov